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Abstract
Background: Although advances in the reduction of maternal mortality have been made, up to 273,000 women will die this
year from obstetric etiologies. Obstructed labor (OL), most commonly treated with Caesarean delivery, has been identified
as a major contributor to global maternal morbidity and mortality. We used economic and epidemiological modeling to
estimate the cost per disability-adjusted life-year (DALY) averted and benefit-cost ratio of treating OL with Caesarean
delivery for 49 countries identified as providing an insufficient number of Caesarean deliveries to meet demand.
Methods and Findings: Using publicly available data and explicit economic assumptions, we estimated that the cost per
DALY (3,0,0) averted for providing Caesarean delivery for OL ranged widely, from $251 per DALY averted in Madagascar to
$3,462 in Oman. The median cost per DALY averted was $304. Benefit-cost ratios also varied, from 0.6 in Zimbabwe to 69.9
in Gabon. The median benefit-cost ratio calculated was 6.0. The main limitation of this study is an assumption that lack of
surgical capacity is the main factor responsible for DALYs from OL.
Conclusions: Using the World Health Organization’s cost-effectiveness standards, investing in Caesarean delivery can be
considered ‘‘highly cost-effective’’ for 48 of the 49 countries included in this study. Furthermore, in 46 of the 49 included
countries, the benefit-cost ratio was greater than 1.0, implying that investment in Caesarean delivery is a viable economic
proposition. While Caesarean delivery alone is not sufficient for combating OL, it is necessary, cost-effective by WHO
standards, and ultimately economically favorable in the vast majority of countries included in this study.
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Introduction
In 2011, pregnancy-related complications resulted in an
estimated 273,500 maternal deaths globally, or close to 775
deaths per day [1]. Regrettably, up to 90% of these deaths are
preventable if diagnosed and treated in a timely manner [2].
Maternal mortality is a tragedy in any country, yet some face a
much greater burden than others. Ninety-nine percent of maternal
deaths occur in developing countries, and 65% occur in just 11
countries: Afghanistan, Bangladesh, the Democratic Republic of
the Congo, Ethiopia, India, Indonesia, Kenya, Nigeria, Pakistan,
Sudan, and Tanzania [3]. The majority of maternal deaths can be
traced to five causes: postpartum hemorrhage, infection, obstruct-
ed labor leading to hemorrhage or infection, hypertensive
disorders, and unsafe abortion [4]. Among these etiologies, one
of the most common in developing countries is obstructed labor,
defined by the World Health Organization (WHO) as labor in
which ‘‘the presenting part of the fetus cannot progress into the
birth canal, despite strong uterine contractions [5].’’ In the
majority of cases, the risks posed by obstructed labor can only be
averted by operative delivery of the fetus, which is most often by
Caesarean delivery [5,6,7]. For the estimations and calculations in
this study, obstructed labor (OL) is meant to indicate cases that are
neglected or left untreated.
Premature death is not the only consequence of neglected
obstructed labor: for every maternal death, there are many more
cases of disabling sequelae, most commonly obstetric fistula [5].
An obstetric fistula is an abnormal communication between the
rectum and vagina (rectovaginal fistula) or the bladder and vagina
(vesicovaginal fistula). According to the United Nations Population
Fund (UNFPA), as many as 3 million women are believed to suffer
from obstetric fistula and another 30,000 to 130,000 cases develop
each year in Africa alone [8]. Fistulas are devastating for the
women who endure them: victims are often banned from their
homes and shunned from their communities [8,9]. Most affected
women go without treatment for the duration of their lives despite
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broadly, the effects of poor obstetric care in the developing world
are not confined to the mother and child; the loss of productivity,
destabilization of families and diversion of resources resulting from
complications of OL amplify poverty within an individual
household and the community at large [10].
Maternal death and obstetric fistula are preventable with timely
diagnosis and treatment of obstructed labor, but this requires
access to emergency obstetric systems, a service unavailable to
most mothers in developing countries [11,12]. Several studies have
correlated the expansion of emergency obstetric services in
developing countries with dramatically lowered rates of maternal
mortality in the targeted regions [13,14,15]. With increased
investment in health systems over the last two decades, the global
maternal mortality ratio has decreased by 34% from its peak in
1990 [1,3].
Despite the above-mentioned success in reducing maternal
mortality, only 13 developing countries are on track to reach
Millennium Development Goal (MDG) Five, which calls for a
75% reduction in maternal mortality ratios by 2015 [1]. Although
international funding for maternal health has doubled in the last 5
years, it is still below the projected level necessary to reach MDG5
and is not aligned with countries that have the highest maternal
mortality ratios [16]. Insufficient funding for maternal health
remains a significant dilemma for international aid organizations
and governments.
Quantifying the cost and benefit of averting the consequences of
OL is essential for accurate analysis and informed health system
funding prioritization [2,10,17]. The present study evaluates the
impact of treating OL with Caesarean delivery in 49 countries,
across multiple regions, identified by the WHO as providing an
insufficient number of Caesarean deliveries to meet current
demand [18]. Using previously published methodologies [19,20]
that estimate the number of disability-adjusted life-years (DALYs)
averted secondary to a surgical intervention, convert said DALYs
into estimates of economic impact for the affected populations,
and compare the potential economic benefit with the cost of
providing the surgical intervention, we determine a country-
specific cost per DALY averted and benefit-cost ratio for providing
Caesarean delivery in the context of OL. To our knowledge, this is
the first study to quantify, in monetary terms, both the cost and
benefit of treating OL with Caesarean delivery.
Methods
Study Cohort: Estimating the incidence of neglected
obstructed labor and its sequelae
The relevant population in this study is the estimated number of
women that incurred OL in 2008 in each of 49 countries noted by
the World Health Organization as providing an insufficient
number of Caesarean deliveries [18]. To estimate the number of
cases of OL, we used a modeling approach based on publicly
available retrospective data from the World Bank, U.N., and
global burden of disease (GBD) study [21,22,23]. The GBD study
[23] has included estimates of the incidence of OL and its sequelae
since its inception. Our study relies on epidemiological estimates
from the GBD study as the basis for our incidence and DALY
calculations. Like the GBD study, we assume that left untreated,
obstetric fistula is a permanent sequela once present in survivors of
OL. Although the GBD study has traditionally included stress
urinary incontinence (SUI) as a sequela of OL, recent evidence
argues against a direct role of OL in the pathogenesis of SUI [24],
and so we exclude SUI from our DALY estimates.
The epidemiological assumptions for this study are based on a
GBD working paper from 2003, subsequent GBD reports, and
systemic reviews [4,5,25,26,27,28]. The GBD studies estimate the
incidence of OL and its sequelae—obstetric fistula and maternal
mortality—by WHO sub-region. Countries from the aforemen-
tioned WHO cost study were assigned to their appropriate WHO
sub-region and subsequently assigned the incidence rates specific
to the sub-region to which they belong. The WHO Caesarean
delivery cost study included 54 counties; five countries included in
the cost study—Azerbaijan, Kyrgyzstan, Tajikistan, Turkmeni-
stan, and Uzbekistan—belonged to a sub-region in which the
GBD study estimated 0.0 cases of OL. These countries are not
included in our analysis.
Our estimates differ from the GBD studies as we only included
women ages 15–49, as opposed to ages 15–59. We used the former
as female fecundity is thought to approach 0% by age 45 [29].
Another key difference is that the GBD working paper [5]
estimates a blanket incidence rate for all fertile women; since
DALYs are sensitive to the age at which a patient incurs a disease
process (due to age-weighting and changes in life-expectancy),
efforts were made to apportion the incidence of OL and its
sequelae (rectovaginal and vesicovaginal fistula, maternal death)
according to seven female age-groups: 15–19, 20–24, 25–29, 30–
34, 35–39, 40–44, and 45–49. This was accomplished by: i)
calculating the total number of births in each of these age groups
for every included country in 2008; ii) dividing the number of
births in each age group by total births to calculate the relative
proportion each age group contributes to total births; iii)
calculating the total number of cases of OL and its sequelae for
all women 15–49 using the incidence rates from the GBD working
paper; and iv) multiplying the age-specific proportions from (ii) by
the total number of cases of OL or its sequelae from (iii). An
important limitation of this approach is that it does not account for
the relationship between parity and obstructed labor: younger
women are thought to have increased rates of OL because they are
more likely to be nulliparous. Nevertheless, assigning different
rates of OL to age groups by birth rate is still more granular than
designating one rate for all women.
Establishing the cost of a Cesarean Delivery
As part of a background report for the 2010 World Health
Report, the World Health Organization (WHO) estimated the
unit cost of a Caesarean delivery for 49 countries that were
identified as providing an insufficient quantity to meet demand
[18]. The inputs for estimating cost included ‘‘… initiation of
labour at referral level, diagnosis of obstructed labour and referral,
Caesarean delivery associated devices and medicines, operative
facility time, medical human resources time, management of shock
including hysterectomy and blood transfusion (assumed for 1% of
CS performed), postoperative hospital stay for stabilization …
programme administration, training, and the corresponding office
space, electricity and other services, as well as a variety of standard
consumables and equipment [18].’’ The estimated unit cost of a
Caesarean delivery in each country is not explicitly stated in the
report; instead, the total number of additional necessary Caesar-
ean deliveries and total cost to provide said Caesarean deliveries
are presented for each country. To obtain an average cost per
Caesarean delivery for each country from this study, we divided
the cost of supplying the necessary additional Caesarean deliveries
by the number of additionally needed Caesarean deliveries to
satisfy demand.
Costs and Benefits of Caesarean Delivery
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economic benefits of treatment
A thorough overview of the DALY and the methods used to
approximate the economic costs and benefits of surgical treatment
are presented elsewhere (Appendix S1) [19,20]. The following
provides a brief explanation of the essential concepts and
terminology that are necessary for understanding the methods
and results of this study.
The DALY is a health metric that attempts to describe
quantitatively the morbidity and mortality secondary to a disease
process or risk factor in a population. One DALY is equivalent to
the loss of one healthy year of life due to either early death or
disability. Therefore, public health practitioners wish to avert
DALYs in a population. To estimate the years lost while living
with a disability, a predefined ‘‘disability weight’’ is multiplied by
the number of years lived with the disability, where 0=complete
health and 1=death. The benefit of a surgical intervention can be
described in terms of the number of DALYs said intervention
averts.
Importantly, not all Caesarean deliveries are meant to address
OL, and not all cases of OL are treated with Caesarean delivery.
To align with the GBD study, we estimated that 90% of OL cases
require Caesarean delivery, while the remaining 10% can be
addressed with instrumental vaginal delivery [5,28]. These latter
cases are excluded from our analysis.
In this study, we estimated the number of DALYs that could be
averted in the 49 countries included in the WHO cost study if 90%
of cases of OL were prevented in a timely fashion with a
Caesarean delivery. Since Caesarean delivery is assigned a
disability weight by the GBD study and carries a risk of mortality
[30], we first calculated the gross number of DALYs that would be
averted by preventing 90% of OL cases, and then subtracted the
number of DALYs that would be incurred secondary to Caesarean
deliveries to arrive at net DALYs averted.
DALYs can be calculated under different assumptions. The two
most important ones pertain to discounting and age weights.
Discounting the value of future DALYs to their present value is
common practice and improves the economic comparability of
DALYs that occur at different points of time. All of our DALY
estimates are therefore discounted. We used a 3% discount rate,
which has been used both in studies by the architects of the DALY
concept [31] and in studies by experts on valuing mortality risk
reductions [32]. The stated justification for age weighting in the
DALY literature is that the social value of a year of healthy life is
greater for young adults than for children or older adults. An age-
weighting parameter, b, determines the age at which the DALY
function peaks, with the peak occurring at 1/b. The most common
value of b in the DALY literature is 0.04, which implies a peak at
age 25. As described below, however, we used an alternative,
country-specific age-weighting parameter, denoted by ~ b b, which is
more consistent with empirical evidence on valuation of health
risks.
To value a DALY in monetary terms, we adapted an economic
concept known as the ‘‘value of a statistical life’’ (VSL). The VSL
concept, grounded firmly in economic theory, uses empirical
information on individuals’ own valuation of the benefits of
reducing the risk of premature death [33]. For example, a
willingness to incur a cost of $100 in order to reduce the risk of
death by 1/10,000 implies a VSL of at least $1 million
(=$10041/10,000). VSL estimates are obtained either from
survey data or empirical wage data and are used in benefit-cost
analyses by government agencies in the United States and other
countries [34].
VSL studies have been performed in relatively few developing
countries, but economists have devised a method for estimating
the VSL in a country in which empirical studies have not been
performed [35]. Using the ratio of gross national income per
capita (GNI/capita) as a conversion factor, one can transfer the
VSL from a higher-income country in which empirical studies
have been performed to a lower-income country in which they
have not. The key parameter in this transfer method is the
‘‘income elasticity of VSL’’ (IE-VSL), which determines how VSL
changes in proportion to the relative income of the two considered
countries. As IE-VSL increases, the transferred VSL estimate in
the lower-income country decreases. Values of IE-VSL for
transfers between developed and developing countries are typically
in the range of 0.5–1.0, although some recent evidence suggests
that even higher values are more appropriate for transfers to very
low-income countries [36]. To err on the side of not exaggerating
the benefits of addressing OL, this study uses an IE-VSL value of
1.5 for each included country.
Although VSL is defined in reference to reduced mortality risk,
government agencies in the U.S. and abroad have used it to value
decreased morbidity as measured by averted DALYs or their
mirror image, quality-adjusted life-years (QALYs) [37,38]. Health
interventions such as Caesarean delivery for OL address both
mortality (decreased maternal death) and morbidity (decreased
rates of obstetric fistula), and so an analysis that valued only
mortality reduction would underestimate the benefits of the
intervention. Valuing averted DALYs using the VSL approach
requires converting VSL to its annualized equivalent, the ‘‘Value
of a Statistical Life-Year’’ (VSLY). Recent evidence on how
individuals of different ages value reductions in mortality risks
indicates that the VSLY changes with age, peaking at about 2/3 of
life-expectancy [32]. To create consistency between DALYs and
the VSLY estimates used to value them, we modified the DALY
formula so that the age-weighting function peaks at 2/3 of a
country’s life expectancy, not a fixed 25 years as is the case with
the commonly used b=0.04. This modification is indicated by the
notation ~ b b, which signifies that we used country-specific age
weights.
Like previous studies, we use the following notation to indicate
the set of assumptions used in calculating DALYs: DALYs (r,K,b),
where r=the discount rate, K=modulation of age-weighting
formula (0=age weights off, 1=age weights on), and b=age-
weighting parameter. For example, DALYs (3,0,0) indicates a 3%
discount rate and no age weighting, while DALYs (3,1,~ b b) indicates
a 3% discount rate and country-specific age weights.
Estimating the Cost per DALY averted and Benefit-Cost
Ratio
To estimate the total cost of providing the necessary number of
Caesarean deliveries to prevent OL’s sequelae, we multiplied the
country-specific unit cost of a Caesarean delivery by the number of
Caesarean deliveries required to treat 90% of the cases of OL in
that country. Once the total country-specific cost was calculated,
we divided said cost by the total number of DALYs (3,0,0) that
Caesarean delivery for OL was estimated to avert. We chose
DALYs (3,0,0) to allow our estimates to be compared to the
interventions listed in Disease Control Priorities in Developing Countries:
2
nd Edition (DCPP) [39]. To calculate the benefit-cost ratio, we
divided the country-specific economic benefit of treating OL by
the total cost of providing the Caesarean deliveries required to do
so, where the estimated benefit was based on DALYs (3,1,~ b b).
Costs and Benefits of Caesarean Delivery
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preventable obstetric fistulas and maternal mortality for each country in 2008.
Country Caesarean Deliveries
a Preventable Obstetric Fistulas Preventable Maternal Mortality
b
Algeria 54,600 1,160 690
Bangladesh 170,800 3,670 420
Benin 10,800 230 140
Burkina Faso 20,000 430 250
Cambodia 3,700 80 0
Cameroon 24,900 530 320
Central African Republic 5,300 110 70
Chad 13,200 280 170
Comoros 900 20 10
Co ˆte d’Ivoire 22,800 480 310
Democratic Republic of the Congo 72,600 1,540 980
Eritrea 6,500 140 90
Ethiopia 97,800 2,070 1310
Gabon 2,000 40 30
Ghana 31,200 660 400
Guinea 12,000 260 150
Haiti 6,500 140 (10)
India 1,315,700 28,230 3220
Indonesia 83,400 1,730 320
Kenya 48,700 1,030 660
Lesotho 2,800 60 40
Liberia 4,700 100 60
Libyan Arab Jamahiriya 1,400 30 0
Madagascar 25,000 530 320
Malawi 16,200 340 220
Mali 18,000 380 230
Mauritania 4,500 100 60
Mongolia 500 10 0
Morocco 30,500 640 150
Mozambique 27,800 590 370
Nepal 31,900 690 80
Niger 17,200 370 220
Nigeria 190,200 4,050 2420
Oman 500 10 0
Pakistan 144,900 3,050 710
Philippines 10,300 250 0
Rwanda 13,000 280 170
Senegal 15,700 330 200
Sierra Leone 7,600 160 100
Sudan 33,900 710 160
Swaziland 1,500 30 20
Togo 7,900 170 100
Tunisia 2,400 50 0
Uganda 35,500 750 480
United Republic of Tanzania 50,300 1,070 680
Viet Nam 25,000 550 (20)
Yemen 18,000 380 90
Zambia 14,300 300 190
Costs and Benefits of Caesarean Delivery
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Estimated Incidence of OL and its Sequelae in 2008
A total of 3.1 million cases of OL are estimated to have occurred
in the 49 countries included in this study in 2008. For each
country, Table 1 presents the estimated number of Caesarean
deliveries necessary to treat 90% of OL, along with the number of
cases of obstetric fistula and maternal death that would be
prevented by providing Caesarean delivery for OL. Maternal
mortality is adjusted to account for mortality secondary to
Caesarean delivery. For the 49 countries, an estimated 2.8 million
Caesarean deliveries would have prevented 59,100 cases of
obstetric fistula and 16,800 maternal deaths.
Total DALYs Averted by Treating OL in 2008
Table 2 presents the total number of country-specific DALYs
(3,0,0) and DALYs (3,1,~ b b) that would be averted if 90% of OL
cases were treated by the provision of Caesarean deliveries in
2008. A total of 950,000 DALYs (3,0,0) or 1.1 million DALYs
(3,1,~ b b) could be averted by providing the necessary number of
Caesarean deliveries to treat OL. The similarity of these estimates
indicates that the total number of DALYs averted is not very
sensitive to the different assumptions about age-weighting.
The costs and benefits of providing Caesarean deliveries
to prevent OL in 2008
Table 3 presents the total cost of providing the necessary
number of Caesarean deliveries to prevent all cases of OL for the
included countries in 2008, estimated by multiplying the total
number of cases of OL (and thus the total number of Caesarean
deliveries that need to be provided) by the unit cost of a Caesarean
delivery. For each country, the total cost of providing Caesarean
deliveries for OL was then divided by the potential DALYs averted
if all cases of OL were treated to create a cost per DALY averted;
as noted earlier, we used DALYs (3,0,0) in this calculation, to
facilitate comparison to the estimates reported in DCPP. The cost
per DALY averted varied by country, ranging from $251 to $3,462
per DALY. The median cost per DALY averted was $304.
Table 3 also presents the country-specific gross economic
benefit of preventing OL, using DALYs (3,1,~ b b). The total benefit
across countries was estimated to be $4.3 billion. The last column
of Table 3 shows benefit-cost ratios for providing Caesarean
deliveries in each country, calculated by dividing the estimated
economic benefit by the total cost of providing Caesarean
deliveries. The benefit-cost ratio ranges from 0.6 for Zimbabwe
to 69.9 for Gabon, with a median value of 6.0.
Discussion
This study attempts to quantify the cost and benefit of treating
neglected obstructed labor (OL) with Caesarean delivery. The
global and regional burden of OL in terms of incidence,
contribution to total deaths, and contribution to global DALYs
has previously been described in the ongoing global burden of
disease studies (GBD) [23,26,40]. As noted above, our study
utilizes the epidemiological assumptions made by the GBD—with
modifications to account for the fact that birth rates vary by age—
to estimate the country-specific incidence of OL and its sequelae.
For the 49 countries included in this study, 2.8 million cases of OL
in 2008 were estimated to result in 59,100 cases of vesicovaginal or
rectovaginal fistula and 16,800 maternal deaths. Given that these
sequelae can be prevented with timely diagnosis, referral, and
access to Caesarean delivery, these figures, although already
known in global and regional terms, remain striking.
We also present an estimate of the total number of DALYs,
calculated using the two sets of assumptions described above, that
could be prevented with access to Caesarean delivery (Table 2).
Without further context, these numbers have little meaning.
However, when paired with the cost to prevent said DALYs with
Caesarean delivery, a cost per DALY averted can be estimated,
and comparisons can be made with other interventions with a
known cost per DALY averted. Annex 2.B of the second edition of
DCPP lists the cost per DALY (3,0,0) averted for more than 100
interventions, ranging from highly active anti-retroviral treatment
for HIV positive individuals ($350-$1494/DALY averted in sub-
Saharan Africa) to population-based immunization against rota-
virus ($2,478–$2,945/DALY averted) [39]. Surgical interventions
presented in DCPP include Trichiasis surgery ($39/DALY
averted), cataract extraction ($180/DALY averted), and carotid
endarterectomy for stroke prevention ($1,458/DALY averted). We
estimate that Caesarean delivery for OL, depending on the
country, costs $251 to $3,462 per DALY (3,0,0), with a median
cost of $304 per DALY in the 49 countries included in this study.
It thus compares favorably to the costs reported in DCPP; in fact,
our median cost estimate is less than 46% of the cost per DALY
estimates for interventions reported in DCPP.
The WHO, building upon work by the Commission on
Macroeconomics and Health, has suggested thresholds for
determining whether an intervention should be considered cost-
effective: an intervention that costs more than three times the gross
national income per capita (GNI/capita) per DALY is not
considered cost-effective, an intervention that costs between one
and three times the GNI/capita per DALY is considered cost-
effective, and an intervention that costs less than the GNI/capita
per DALY is considered highly cost-effective [17,41]. By these
standards, Caesarean delivery for OL is ‘‘highly cost-effective’’ in
every country we examined except Zimbabwe, which still has a
cost per DALY averted that qualifies as ‘‘cost-effective.’’
Although economic analyses in the current global health
literature are dominated by discussions of cost-effectiveness, there
is growing interest in valuing improvements in health with
measures that take into account the improvement in economic
welfare that a longer, healthier life provides [39,42]. Table 3
presents our economic valuation of potential DALYs averted by
Caesarean delivery. Viewed in isolation, the estimates of the
economic benefit of investing in Caesarean delivery for OL are
Table 1. Cont.
Country Caesarean Deliveries
a Preventable Obstetric Fistulas Preventable Maternal Mortality
b
Zimbabwe 16,100 340 220
Total 2,771,000 59,150 16,800
aNecessary to prevent 90% of OL;
bAdjusted for mortality secondary to Caesarean delivery.
doi:10.1371/journal.pone.0034595.t001
Costs and Benefits of Caesarean Delivery
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compared to the cost of the intervention. In a recent study,
Jamison et al. also combined the potential cost of global health
interventions with the potential economic benefit by valuing
DALYs with a VSL approach, ultimately estimating benefit-cost
ratios for seven interventions [42]. A key difference between their
approach and ours, however, is that Jamison et al. assigned a
blanket value of $1000 or $5000 to an averted DALY, based on
the assumption that the VSLY is roughly 2–4 times per capita
income. Our approach [Appendix S1] is more finely tuned to
country characteristics, as it estimates a VSLY that varies with per
capita income, life expectancy, age, and, if desired, the IE-VSL.
The benefit-cost ratios in Table 3 convey the fundamental
finding of this study: the benefit-cost ratio is greater than one for
every country we examined except Zimbabwe, Liberia, and
Democratic Republic of the Congo; investment in Caesarean
delivery will therefore not only reduce the tragic consequences of
OL but will also yield an economic benefit that exceeds the cost.
The median benefit-cost ratio for the 49 countries included in our
study is 6:1, which represents an excellent return on investment.
Actual benefit-cost ratios might be even higher than we calculated,
as we conservatively used the largest IE-VSL value (=1.5)
reported in the literature, which reduces the estimated benefits.
Even Zimbabwe, Liberia and Democratic Republic of the Congo
have benefit-cost ratios greater than one if we instead use IE-
VSL=1, which is the most common value used in cross-country
studies.
Our study has a number of important implications for non-
governmental organizations (NGOs), governmental organizations,
and academicians. For potential donors and NGOs, we emphasize
the relative cost-effectiveness of Caesarean delivery for OL in
comparison to other interventions and WHO’s per capita income
thresholds. Our analysis is particularly useful if one is concerned
with averting the most DALYs per dollar invested; the cost per
DALY averted for each country can be ranked from lowest to
highest and plotted against cumulative DALYs averted (Figure 1).
Cost-conscious donors should begin by investing in the left-most
country and moving progressively to the right until all funds are
used. Our analysis further suggests that when prioritizing national
funding priorities, governments should recognize that investment
in healthcare can achieve net-positive economic benefits, as
indicated by benefit-cost ratios greater than one. According to this
metric, allocating sufficient annual funding for providing Caesar-
ean deliveries within the broader context of maternal healthcare is
an excellent economic proposition in almost all the countries we
considered.
Our analysis has a number of important limitations. The most
important is the implicit assumption that insufficient surgical
capacity is main factor responsible for DALYs associated with
90% of OL. Our estimates of the benefits of Caesarean delivery to
address OL are biased upward if, as the literature indicates, other
Table 2. Estimated number of DALYs averted if the sequelae
of OL were prevented by Caesarean delivery.
DALYs averted
Country (3,0,0) (3,1,~ b b)
Algeria 29400 32700
Bangladesh 45700 51300
Benin 5400 6100
Burkina Faso 9900 11200
Cambodia 700 800
Cameroon 12000 13700
Central African Republic 2500 2900
Chad 6300 7200
Comoros 500 500
Co ˆte d’Ivoire 11500 13100
Democratic Republic of the
Congo
36900 41800
Eritrea 3600 4000
Ethiopia 50700 57000
Gabon 1000 1200
Ghana 16200 18100
Guinea 6000 6800
Haiti 1200 1400
India 346900 392700
Indonesia 24600 27700
Kenya 24400 27800
Lesotho 1200 1500
Liberia 2400 2700
Libyan Arab Jamahiriya 200 300
Madagascar 12800 14300
Malawi 7900 9100
Mali 8700 9900
Mauritania 2300 2600
Mongolia 100 100
Morocco 10500 11600
Mozambique 13100 15100
Nepal 8400 9500
Niger 8400 9600
Nigeria 90900 104000
Oman 100 100
Pakistan 47400 52900
Philippines 2700 3000
Rwanda 6900 7800
Senegal 8100 9100
Sierra Leone 3700 4300
Sudan 10700 12100
Swaziland 700 800
Togo 4100 4600
Tunisia 400 500
Uganda 17600 20100
United Republic of Tanzania 24400 28100
Viet Nam 5300 5900
Yemen 5800 6600
Table 2. Cont.
DALYs averted
Country (3,0,0) (3,1,~ b b)
Zambia 6700 7800
Zimbabwe 6000 7500
Total 952,900 1,079,500
doi:10.1371/journal.pone.0034595.t002
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Country
Unit Cost of
Caesarean delivery Total Cost (000 s)
a Cost/DALY averted
b
Gross Economic
Benefit (000 s)
c
Benefit-Cost
Ratio
d
Algeria $200 $10,930 $372 $738,500 67.6
Bangladesh $98 $16,760 $367 $90,400 5.4
Benin $142 $1,530 $281 $11,000 7.2
Burkina Faso $140 $2,800 $284 $13,900 5.0
Cambodia $148 $550 $743 $2,100 3.8
Cameroon $144 $3,590 $298 $43,300 12.1
Central African Republic $157 $830 $335 $1,800 2.2
Chad $140 $1,840 $293 $8,000 4.4
Comoros $141 $130 $273 $700 5.2
Co ˆte d’Ivoire $153 $3,490 $304 $26,300 7.5
Democratic Republic of the Congo $131 $9,550 $259 $6,200 0.6
Eritrea $139 $910 $254 $1,700 1.9
Ethiopia $133 $12,980 $256 $46,900 3.6
Gabon $361 $730 $709 $50,700 69.9
Ghana $136 $4,240 $262 $32,800 7.7
Guinea $130 $1,560 $258 $6,200 4.0
Haiti $154 $1,010 $835 $1,600 1.6
India $105 $137,580 $397 $2,060,400 15.0
Indonesia $145 $12,060 $491 $190,500 15.8
Kenya $139 $6,780 $278 $53,900 8.0
Lesotho $202 $570 $469 $3,600 6.3
Liberia $136 $640 $272 $500 0.7
Libyan Arab Jamahiriya $498 $700 $2,886 $17,900 25.6
Madagascar $128 $3,210 $251 $15,400 4.8
Malawi $133 $2,160 $274 $5,800 2.7
Mali $134 $2,420 $278 $12,100 5.0
Mauritania $161 $720 $316 $7,200 9.9
Mongolia $187 $90 $1,026 $700 7.1
Morocco $169 $5,140 $488 $101,200 19.7
Mozambique $137 $3,810 $291 $10,500 2.8
Nepal $97 $3,090 $366 $11,200 3.6
Niger $127 $2,180 $259 $5,600 2.6
Nigeria $138 $26,330 $289 $290,100 11.0
Oman $609 $320 $3,462 $12,300 38.8
Pakistan $154 $22,300 $471 $221,800 9.9
Philippines $152 $1,570 $589 $19,800 12.6
Rwanda $137 $1,790 $259 $8,900 5.0
Senegal $141 $2,220 $275 $21,900 9.9
Sierra Leone $127 $970 $260 $2,900 2.9
Sudan $156 $5,300 $495 $32,400 6.1
Swaziland $226 $350 $508 $8,800 25.5
Togo $132 $1,040 $255 $3,500 3.4
Tunisia $350 $840 $2,017 $9,600 11.5
Uganda $141 $4,990 $284 $24,300 4.9
United Republic of Tanzania $139 $7,020 $288 $41,800 6.0
Viet Nam $149 $3,730 $702 $26,400 7.1
Yemen $156 $2,800 $480 $21,800 7.8
Zambia $149 $2,120 $319 $10,500 4.9
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timely manner or patients being unable to travel to clinics or
hospitals for emergency obstetric care, as could be the case in
remote regions with poor communications and transportation
infrastructure [9,43]. As noted earlier, the WHO cost estimates
attempted to include costs related to ‘‘diagnosis of obstructed
labour and referral,’’ but is possible that increased expenditure
would not overcome barriers to improved diagnosis, referral, and
access. The large benefit-cost ratios that we have estimated
indicate, however, that surgical intervention would still be
economically justified even if the actual number of Caesarean
deliveries successfully performed were far fewer than the perfect
rate we have assumed. At our median estimate of the benefit-cost
ratio, surgical intervention would break even if only 1/6 of the
potentially avertable DALYs were actually averted.
Strong evidence and a wealth of experience suggests that
vertical programming of maternal health interventions, which
Deborah Maine terms ‘‘one-complication programs’’ or ‘‘one-
component programs,’’ are much less successful than interventions
that aim to horizontally bolster health systems and thus address
maternal mortality across the entire spectrum of obstetric care
[44]. We agree, and have no intention of implying that Caesarean
delivery alone is a magic bullet, or that an NGO should be formed
to solely address OL. The current focus on packages of
interventions, such as basic and emergency obstetric care, aim to
ensure that women in need of an emergent Caesarean delivery are
aware of facilities available to them, are properly diagnosed at the
local level, are successfully transported to a referral hospital, and
undergo safe Caesarean delivery in a capable facility [45,46]. And
yet there are still those who believe surgical interventions are too
complex to implement, or that they require too great an
investment to yield substantial gains in health [47]. In this broader
context, our argument is that Caesarean delivery—as part of a
larger strategy— can address maternal mortality in an econom-
ically favorable fashion.
The DALY’s methodological imperfections and philosophical
controversies are well-documented elsewhere [48], and a critique
of our methodology for valuing DALYs is presented elsewhere as
Table 3. Cont.
Country
Unit Cost of
Caesarean delivery Total Cost (000 s)
a Cost/DALY averted
b
Gross Economic
Benefit (000 s)
c
Benefit-Cost
Ratio
d
Zimbabwe $140 $2,260 $376 $1,300 0.6
Median $141 – $304 – 6.0
a: Total cost to treat 90% of cases of neglected obstructed labor with Caesarean delivery.
b: The cost per DALY averted using (3,0,0) assumptions, which is consistent with the DCPP approach.
c: Estimated by valuing DALYs (3,1,~ b b) with value of a statistical life-year.
d: Benefit-cost ratio calculated by dividing gross economic benefit by total cost.
doi:10.1371/journal.pone.0034595.t003
Figure 1. Cost per DALY (3,0,0) averted vs. cumulative DALYs (3,0,0) averted for the 49 countries included in the analysis. The
vertical axis represents the average cost per DALY averted in a country, and the horizontal axis shows the cumulative number of DALYs averted as
one moves from least-cost country to highest-cost country. To maximize the number of DALYs averted within their budgets, cost-conscious donors
should first donate to countries at the left-most portion of curve and then move right until all funds are used.
doi:10.1371/journal.pone.0034595.g001
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estimating VSLs in low-income countries where formal studies
have not been undertaken [36], but in choosing an IE-VSL of 1.5,
we have minimized the risk of overestimation. Our estimates of
cost per DALY averted (third column of Table 3) and benefit-cost
ratios (last column of Table 3) are possibly too conservative (i.e.,
too high and too low, respectively), due to using the lower bound
estimates of DALYs averted (3,0,0) for the former and the upper
bound estimate of IE-VSL (=1.5) for the latter. Most importantly,
we do not account for the reduction in perinatal mortality and
morbidity that would undoubtedly occur with improved access to
Caesarean delivery. Depending on the data source, the perinatal
mortality rate secondary to neglected OL ranges from 38–92%
[6,7,49].
Finally, our results are based on modeling of secondary data.
Although our epidemiologic assumptions are based on the best
available data, there is uncertainty regarding the true number of
maternal deaths worldwide and the contribution that OL makes to
that number.
While improvements in maternal healthcare have been well-
documented [1,3], there is still a chasm between the current reality
and what is ultimately achievable. Although few would deny the
horrific human consequences of neglected obstructed labor and
the consequent need to combat OL for strictly humane purposes,
the notion that surgical intervention is not cost-effective still exists.
We demonstrate that investment in Caesarean delivery is cost-
effective and can yield a net positive economic return within the
context of a horizontally functioning health-system. The analyses
utilized in this paper can be applied to other interventions and are
crucial for better-informed investments in global health care
delivery.
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